{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:08:11Z","timestamp":1788898091760,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ard.2026.07.013","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:36:12Z","timestamp":1787830572000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacodynamic analysis of TYK2 inhibition by deucravacitinib: results from the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4006-8945","authenticated-orcid":false,"given":"J. Michelle","family":"Kahlenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2858-8064","authenticated-orcid":false,"given":"Chun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-4755","authenticated-orcid":false,"given":"Edward","family":"Vital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6220-2626","authenticated-orcid":false,"given":"Ian M.","family":"Catlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7881-2020","authenticated-orcid":false,"given":"Mary K.","family":"Crow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4182-587X","authenticated-orcid":false,"given":"Ignacio","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0098-1083","authenticated-orcid":false,"given":"Amit","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-1664","authenticated-orcid":false,"given":"Cristina","family":"Arriens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5935-7997","authenticated-orcid":false,"given":"Coburn","family":"Hobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8149-5636","authenticated-orcid":false,"given":"Yanhua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2026.07.013_bib0001","first-page":"330","article-title":"Manifestations of systemic lupus erythematosus","volume":"6","author":"Cojocaru","year":"2011","journal-title":"Maedica (Bucur)"},{"key":"10.1016\/j.ard.2026.07.013_bib0002","article-title":"Inflammatory cytokines in systemic lupus erythematosus","volume":"2011","author":"Ohl","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.ard.2026.07.013_bib0003","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.07.013_bib0004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12519-019-00229-3","article-title":"Immunological pathogenesis and treatment of systemic lupus erythematosus","volume":"16","author":"Pan","year":"2020","journal-title":"World J Pediatr"},{"key":"10.1016\/j.ard.2026.07.013_bib0005","doi-asserted-by":"crossref","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ard.2026.07.013_bib0006","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.ard.2026.07.013_bib0007","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41584-021-00606-1","article-title":"Interferon lambda in inflammation and autoimmune rheumatic diseases","volume":"17","author":"Goel","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2026.07.013_bib0008","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ard.2026.07.013_bib0009","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri3806","article-title":"Regulation of antiviral T cell responses by type I interferons","volume":"15","author":"Crouse","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ard.2026.07.013_bib0010","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1089\/jir.2011.0045","article-title":"Type I interferon and systemic lupus erythematosus","volume":"31","author":"Elkon","year":"2011","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.ard.2026.07.013_bib0011","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41423-018-0010-6","article-title":"Type I interferons promote the survival and proinflammatory properties of transitional B cells in systemic lupus erythematosus patients","volume":"16","author":"Liu","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.ard.2026.07.013_bib0012","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.3390\/ijms24043391","article-title":"Tyk2 targeting in immune-mediated inflammatory diseases","volume":"24","author":"Rusi\u00f1ol","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ard.2026.07.013_bib0013","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL system in SLE pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2026.07.013_bib0014","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2567.2007.02796.x","article-title":"Massive interleukin-12-induced interferon-gamma production by interleukin-15-stimulated lamina propria lymphocytes followed by down-regulation of the interleukin-12 receptor","volume":"124","author":"Ebert","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.ard.2026.07.013_bib0015","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1006\/cyto.1997.0269","article-title":"Impaired production of IL-12 in system lupus erythematosus. II: IL-12 production in vitro is correlated negatively with serum IL-10, positively with serum IFN-gamma and negatively with disease activity in SLE","volume":"10","author":"Liu","year":"1998","journal-title":"Cytokine"},{"key":"10.1016\/j.ard.2026.07.013_bib0016","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1007\/s10067-018-4138-7","article-title":"Higher activation of the interferon-gamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: relation to disease activity","volume":"37","author":"Liu","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2026.07.013_bib0017","first-page":"1","article-title":"Significance of interleukin 23 in systemic lupus patients: relation to disease activity and damage indices","volume":"17","author":"Haroon","year":"2023","journal-title":"Biologics"},{"key":"10.1016\/j.ard.2026.07.013_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.637829","article-title":"Role of the IL-23\/IL-17 pathway in rheumatic diseases: an overview","volume":"12","author":"Schinocca","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ard.2026.07.013_bib0019","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1084\/jem.20100086","article-title":"Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice","volume":"207","author":"Scapini","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.ard.2026.07.013_bib0020","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s42003-019-0382-x","article-title":"Gene expression analysis delineates the potential roles of multiple interferons in systemic lupus erythematosus","volume":"2","author":"Catalina","year":"2019","journal-title":"Commun Biol"},{"key":"10.1016\/j.ard.2026.07.013_bib0021","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/jid.2010.244","article-title":"Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFN\u03bb) in cutaneous lupus erythematosus","volume":"131","author":"Zahn","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ard.2026.07.013_bib0022","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41423-018-0024-0","article-title":"NETosis, complement, and coagulation: a triangular relationship","volume":"16","author":"de Bont","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.ard.2026.07.013_bib0023","doi-asserted-by":"crossref","first-page":"14862","DOI":"10.18632\/oncotarget.23206","article-title":"Coagulation cascade and complement system in systemic lupus erythematosus","volume":"9","author":"Liang","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ard.2026.07.013_bib0024","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms16021","article-title":"Transancestral mapping and genetic load in systemic lupus erythematosus","volume":"8","author":"Langefeld","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ard.2026.07.013_bib0025","doi-asserted-by":"crossref","first-page":"363ra149","DOI":"10.1126\/scitranslmed.aag1974","article-title":"Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity","volume":"8","author":"Dendrou","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ard.2026.07.013_bib0026","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.07.013_bib0027","series-title":"SOTYKTU\u00ae (deucravacitinib) [package insert]","year":"2026"},{"key":"10.1016\/j.ard.2026.07.013_bib0028","series-title":"SOTYKTU\u00ae (deucravacitinib) [summary of product characteristics]","year":"2026"},{"key":"10.1016\/j.ard.2026.07.013_bib0029","series-title":"SOTYKTU\u00ae (deucravacitinib) [Australian product information]","year":"2022"},{"key":"10.1016\/j.ard.2026.07.013_bib0030","series-title":"SOTYKTU\u00ae (deucravacitinib) [product information]","year":"2022"},{"key":"10.1016\/j.ard.2026.07.013_bib0031","series-title":"SOTYKTU\u00ae (deucravacitinib) [product monograph]","year":"2022"},{"key":"10.1016\/j.ard.2026.07.013_bib0032","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","article-title":"Phase 2 trial of iberdomide in systemic lupus erythematosus","volume":"386","author":"Merrill","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2026.07.013_bib0033","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.07.013_bib0034","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3390\/biom11070928","article-title":"Clinical and immunological biomarkers for systemic lupus erythematosus","volume":"11","author":"Yu","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ard.2026.07.013_bib0035","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ard.2026.07.013_bib0036","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1089\/jir.2017.0127","article-title":"Development of a validated interferon score using NanoString technology","volume":"38","author":"Kim","year":"2018","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.ard.2026.07.013_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1151695","article-title":"Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients","volume":"14","author":"Qian","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ard.2026.07.013_bib0038","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.4049\/jimmunol.165.10.5970","article-title":"Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus","volume":"165","author":"Odendahl","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.ard.2026.07.013_bib0039","series-title":"Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study","author":"Kahlenberg","year":"2022"},{"key":"10.1016\/j.ard.2026.07.013_bib0040","series-title":"Deucravacitinib reduces interferons, B-cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study. Milan Italy: Poster presentation at EULAR 2023 European Congress of Rheumatology","author":"Kahlenberg","year":"2023"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726004371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726004371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:47:47Z","timestamp":1788896867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726004371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"alternative-id":["S0003496726004371"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.07.013","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamic analysis of TYK2 inhibition by deucravacitinib: results from the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}